A Florida executive admitted to a $500 million COVID-19 testing fraud that turned “no cost” into a nationwide billing machine targeting public health programs.
Story Highlights
- Hasan “Lucas” Seyhun pleaded guilty to conspiracy to commit health care fraud tied to Fast Lab.
- Prosecutors say Fast Lab pitched “no cost” tests, then billed for services not provided.
- The scheme logged over $500 million in fake claims to government-backed programs.
- The case mirrors broader pandemic-era test billing abuses flagged by federal watchdogs.
Federal Guilty Plea Anchors a Massive COVID-19 Billing Case
The United States Attorney’s Office for the Eastern District of Michigan said Hasan “Lucas” Seyhun, 45, of Miami, pleaded guilty to conspiracy to commit health care fraud. Prosecutors tied him to Fast Lab Technologies, a company that offered “no cost” COVID-19 tests to the public. They said the company used customers’ insurance details to submit claims for services that were not provided. The government described more than $500 million in fake claims to public health programs.
The plea follows earlier charges that detailed how Fast Lab billed for services it said happened but did not. Prosecutors said the company claimed antigen tests were observed by medical staff, saliva samples were collected by medical personnel, and laboratory polymerase chain reaction work was done, when those services were not actually delivered as billed. Charging materials also linked the operation to leaders inside the firm during the pandemic testing surge.
How the “No Cost” Pitch Turned Into Big Bills
According to prosecutors, the scheme relied on a simple hook. Fast Lab told people the tests would cost them nothing, steering them to share their personal and insurance information. The company then allegedly used those details to submit large volumes of claims for services that did not occur, or were misrepresented. The government says claims hit Medicare, Medicaid, and other insurance plans, pushing public systems to pay for care never received.
The Justice Department’s health care fraud summaries show related leaders were charged in a superseding action describing about $566 million in alleged false billing. That summary named a chief executive and a medical director, and outlined roles in the claim process. The case places Seyhun’s plea within a wider enforcement sweep tied to pandemic-era health care fraud, where testing volume and fast payments created openings for abuse.
Pandemic Testing Created Known Vulnerabilities
Federal watchdogs warned during the pandemic that “free test” offers could mask aggressive billing. The Office of Inspector General at the Department of Health and Human Services reported that some labs billed questionably high levels of add-on tests alongside COVID-19 tests. Those patterns raised concerns about waste and fraud across Medicare claims, which surged as testing ramped up nationwide in 2020 and 2021.
The former chief operating officer of Fast Lab Technologies pleaded guilty for orchestrating a COVID‑testing fraud scheme that pushed more than $500M in false claims — driving $35M in illicit payouts and pocketing $4.3M himself. Learn more: https://t.co/IG9ABUdbaz pic.twitter.com/Mu6OHo7zQS
— OIG at HHS (@OIGatHHS) September 28, 2026
Those warnings match the Fast Lab playbook described by prosecutors. Easy sign-ups at the front end, large claims on the back end, and thin oversight between the two. In a time of fear and urgency, systems paid faster to get tests done. That speed also lowered barriers for bad actors. This case shows how a “no cost” promise can still drain public funds when billing flows through government-backed programs.
Why This Case Hits a Nerve Across the Aisle
Taxpayers on the left and right see the same problem here. Public money meant for health care was easy to tap, and insiders allegedly took advantage. Many Americans believe the system protects the well connected while missing basic checks that would block fake claims. A guilty plea does not fix those deeper controls. It does, however, confirm that loopholes were real and costly during one of the most stressed periods in recent memory.
For families, the lesson is simple. “No cost” is not the same as “no bill.” Someone pays when insurance is charged, often the taxpayer. For policymakers, the takeaway is also clear. Crisis programs need speed, but they also need guardrails. Better identity checks, claim auditing, and lab oversight can slow fraud without stopping care. The Fast Lab case shows what happens when those safeguards lag behind demand.
What Comes Next in Court and Policy
Seyhun’s guilty plea sets up sentencing, where the court will weigh facts about claims and losses. Prosecutors have framed the scheme as nationwide and wide-ranging, tied to public insurance programs. The Justice Department has made pandemic health care fraud a priority, and related cases continue across the country. This conviction adds pressure for stronger program integrity in any future public health emergency.
Federal agencies will likely expand post-payment reviews of lab claims, especially those tied to add-on testing around COVID-19. Watchdogs have asked for more data sharing between agencies and insurers to flag outliers faster. Those tools, paired with firm penalties, can help close the gaps exposed by this case. The goal is simple: protect patients, protect the purse, and make sure public dollars pay for real care, not paperwork.
Sources:
redstate.com, justice.gov, freerepublic.com
